From Wikipedia, the free encyclopedia
Jump to: navigation, search
Levocetirizine structure 2.svg
Ball-and-stick model of the levocetirizine molecule
Systematic (IUPAC) name
2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
Clinical data
Trade names Xyzal
AHFS/Drugs.com monograph
MedlinePlus a607056
  • US: B (No risk in non-human studies)
Legal status
Routes of
Pharmacokinetic data
Bioavailability High
Protein binding 90%
Metabolism Hepatic 14% CYP3A4
Biological half-life 6 to 10 hours
Excretion Renal and fecal
CAS Registry Number 130018-77-8 N
ATC code R06AE09
PubChem CID: 1549000
ChemSpider 1266001 YesY
KEGG D07402 YesY
Chemical data
Formula C21H25ClN2O3
Molecular mass 388.888 g/mol
 N (what is this?)  (verify)

Levocetirizine (as levocetirizine dihydrochloride) is a third-generation non-sedative[citation needed] antihistamine, developed from the second-generation antihistamine cetirizine. Chemically, levocetirizine is the active enantiomer of cetirizine. It is the R-enantiomer of the cetirizine racemate. Levocetirizine is an inverse agonist that decreases activity at histamine H1 receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief from the typical symptoms of hay fever. It does not prevent the actual release of histamine from mast cells.

The manufacturers claim it to be more effective with fewer side effects than the second-generation drugs; however, there have been no published studies supporting this assertion. A study part-funded by the manufacturer UCB concluded it may be more effective than some other second- and third-generation anti-histamines, but didn't compare it to cetirizine.[1]


Levocetirizine was first launched in 2001 by Belgian pharmaceutical company UCB.

Brand names[edit]

It is sold under the brand names:

  • Xyzal /ˈzzæl/ in Australia, Austria, Croatia, Czech Republic, Finland, France, Ireland (also Rinozal), Lithuania, Netherlands, Portugal, Romania, Taiwan, Turkey, The Philippines, Serbia, Slovakia, Slovenia, South Africa and UK. On May 25, 2007, the United States Food and Drug Administration approved Xyzal, where it is co-marketed by Sanofi-Aventis.
  • Xusal in Germany;
  • Xozal in Greece.
  • Xazal in Spain;
  • Xuzal in Mexico;
  • In Hungary it is marketed as Zilola (made by Richter Gedeon) and Histisynt (Actavis).
  • In India, levocetirizine is marketed by GlaxoSmithKline and UCB under the brand name Vozet and Xyzal, respectively. Torrent Pharma launched UVNIL on the rural market of India.
  • In Pakistan levocetirizine was first launched in a liquid formulation by Novartis Consumer Health Division under the name of T-Day Syrup.
  • In Nepal levocetirizine is available in tablet with brand name Curin manufactured by Beximco Pharma.[2]
  • In China, levocetirizine is known as 左西替利嗪.

Side effects[edit]

Levocetirizine is called a non-sedating antihistamine as it does not enter the brain in significant amounts, and is therefore unlikely to cause drowsiness. However, some people may experience some slight sleepiness, headache, mouth dryness, lightheadedness, vision problems (mainly blurred vision), palpitations and fatigue.[3]


Latest research shows levocetirizine reduces asthma attacks by 70% in children.[4]


The drug is currently available by prescription in the United States. Although the drug was only authorized by the FDA on 25 May 2007, it was already available in most European countries. Like many new drugs it entered the market at a higher price than currently available third and second generation antihistamines. In India, one form of the drug is available as Crohist MK tablets and syrup, a formulation of levocetirizine hydrochloride and montelukast. In India, Crohist MK is a Schedule 'H' drug and may only be prescribed by a registered medical practitioner. In Finland, Hungary and China,[5] the drug is sold over-the-counter.

Different brands (Actavis, Glenmark, UCB) Levocetirizine tablets and oral solution.


  1. ^ Grant, JA; Riethuisen, JM; Moulaert, B; DeVos, C; Gamalero, C.; Descalzi, D.; Folli, C.; Passalacqua, G.; Canonica, G.W. (February 2002). "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects". Ann Allergy Asthma Immunol 88 (2): 190–197. doi:10.1016/S1081-1206(10)61995-3. PMID 11868924. 
  2. ^ http://www.beximco-pharma.com/allergic-disorders/147-curin.html
  3. ^ XOZAL technical specifications booklet.
  4. ^ Pasquali, M; Baiardini, I; Rogkakou, A; Riccio, AM; Gamalero, C; Descalzi, D; Folli, C; Passalacqua, G; Canonica, GW (September 2006). "Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters". Clinical & Experimental Allergy 36 (9): 1161–7. doi:10.1111/j.1365-2222.2006.02548.x. PMID 16961716. 
  5. ^ On different names: http://www.hazipatika.com/gyogyszerkereso/termek/sefaller_5_mg_filmtabletta/54120

External links[edit]